KRAS and neoplasm: Thus, our findings provide rationale to co-target changes in the tumor microenvironment to prevent non-genetic mechanisms of resistance to KRAS inhibitors observed in roughly one-third of sotorasib-treated NSCLC patients (30), which will guide precision medicine for lung cancer patients.